Exane Derivatives Ngm Biopharmaceuticals Inc Transaction History

Exane Derivatives

  • $157 Million
  • Q2 2022

A detailed history of Exane Derivatives transactions in Ngm Biopharmaceuticals Inc stock. As of the latest transaction made, Exane Derivatives holds 12 shares of NGM stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12
Previous 2,289 99.48%
Holding current value
$0
Previous $34,000 100.0%
% of portfolio
0.0%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022
SELL
$10.58 - $17.5 $24,090 - $39,847
-2,277 Reduced 99.48%
12 $0
Q1 2022

Apr 22, 2022
BUY
$13.81 - $18.6 $2,541 - $3,422
184 Added 8.74%
2,289 $34,000
Q4 2021

Jan 28, 2022
BUY
$17.26 - $22.02 $34,727 - $44,304
2,012 Added 2163.44%
2,105 $37,000
Q3 2021

Oct 26, 2021
SELL
$20.15 - $26.19 $22,064 - $28,678
-1,095 Reduced 92.17%
93 $1,000
Q2 2021

Jul 28, 2021
SELL
$15.06 - $30.03 $80,586 - $160,690
-5,351 Reduced 81.83%
1,188 $23,000
Q1 2021

Apr 30, 2021
BUY
$24.99 - $31.93 $17,992 - $22,989
720 Added 12.37%
6,539 $190,000
Q4 2020

Jan 27, 2021
BUY
$16.21 - $31.44 $94,325 - $182,949
5,819 New
5,819 $176,000

Others Institutions Holding NGM

# of Institutions
5
Shares Held
2.6M
Call Options Held
300
Put Options Held
0
View Full List

About NGM BIOPHARMACEUTICALS INC

NGM Quotes by TradingView
  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email